Table 1.

The distribution of the clinical and pathologic features of all patients in this study was balanced between cases and controls (when patients were split by ERG status SV invasion became unbalanced)

A. Clinical and pathologic features of the patients in the case-control study
FeatureCase (n = 141)Control (n = 117)P
Age at surgery
    Mean (SD)63.8 (7)64.1 (6.4)0.7
    Median6565
    Range(47–77)(50–76)
Preoperative PSA (ng/mL)
    Median11.411.30.996
    Q1, Q31.3, 23.31.6, 21.1
    Range1.3–1431.6–119
Gleason score
    787 (61%, 1.18)63 (54%, 0.79)0.25
    8+54 (39%, 2.18)54 (46%, 1.35)
Pathologic stage, 1997 TNM
    T2aN08 (6%)11 (9%)0.25
    T2bN021 (15%)21 (18%)
    T3aN031 (22%)30 (26%)
    T3b4N050 (36%)27 (23%)
    TxN+30 (21%)28 (24%)
Margin Positive88 (63%)78 (67%)0.53
Adjuvant Hormonal Treatment55 (39%)46 (39%)0.99
Adjuvant Radiation Treatment16 (11%)15 (13%)0.77
B. Clinical and pathologic features according to ERG status
ERG(+)ERG(−)
Cases, n = 56Controls, n = 56Cases, n = 83Controls, n = 57
GS 739 (70%)33 (59%)46 (55%)26 (46%)
GS 8+17 (30%)23 (41%)37 (45%)31 (54%)
SV invasion negative28 (50%)29 (52%)46 (55%)44 (77%)
SV invasion positive28 (50%)27 (48%)37 (45%)13 (23%)
Nodal status negative44 (79%)38 (68%)66 (80%)48 (84%)
Nodal status positive12 (21%)18 (32%)17 (20%)9 (16%)
Margin status negative15 (27%)16 (29%)36 (43%)21 (37%)
Margin status positive41 (73%)40 (71%)47 (57%)36 (63%)

NOTE: In B, the numbers in parentheses are the percentage of corresponding patients compared with all patients in that category (n). Unknown ERG status, n = 6.